Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Faron:

Research 12.03.2026 klo 10.27 by Antti Siltanen
Faron Pharmaceuticals

New partnership for Aiforia

Analyst Comment 11.03.2026 klo 08.49 by Antti Siltanen
Aiforia Technologies

Terms of Faron's rights offering have been published

Analyst Comment 11.03.2026 klo 08.33 by Antti Siltanen
Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Bioretec is planning rights issue worth 5-15 MEUR

Analyst Comment 11.03.2026 klo 08.45 by Antti Siltanen
Bioretec

Aiforia H2'25: Green shoots on the clinical side

Research 09.03.2026 klo 10.51 by Antti Siltanen
Aiforia Technologies

Nightingale H1'26: Research projects accelerate H2

Research 06.03.2026 klo 11.44 by Antti Siltanen
Nightingale Health

Herantis H2'25: Secure financing and initiate new study

Research 06.03.2026 klo 11.39 by Antti Siltanen
Herantis Pharma

Faron H2'25: High stakes in financing success

Research 05.03.2026 klo 10.33 by Antti Siltanen
Faron Pharmaceuticals

Aiforia H2'25 preview: Will customer wins turn into growth?

Analyst Comment 04.03.2026 klo 09.01 by Antti Siltanen
Aiforia Technologies

Faron H2'25 preview: Funding the research program is the next endeavor

Analyst Comment 03.03.2026 klo 09.15 by Antti Siltanen
Faron Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.